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INTRODUCTION
The low mortality with cardiovascular disease in women
is partly due to estrogen, which has many biologic effects
including anti-atherogenic action. Phytoestrogen, a kind of
soyprotein, has a weak but similar action with estrogen on
atherosclerosis. Adlercreutz (1) suggests that populations
that consume a high phytoestrogen diet have a lower risk of
cardiovascular disease and cancer. The lower incidence of
cardiovascular disease in Asian countries and in vegetarians
suggests that phytoestrogens may be cardioprotective. 
Genistein is a principal isoflavone found in soy phytoestro-
gen, and it has structural similarity with 17 -estradiol. Phyto-
estrogen shows many anti-atherogenic activities. It decreases
cholesterol concentration (2), lowers blood pressure (3) and in-
crease HDL cholesterol (4). Genistein inhibits vascular smooth
muscle cell proliferation (5), improves arterial compliance (6, 7)
and it has an antioxidant action (8, 9). Therefore, dietary phy-
toestrogen may inhibit atherosclerosis through these actions.
Studies of clinical events with atherosclerosis provide that
plaque stability seems a more important factor than lesion
size (10). Activated T lymphocytes in atherosclerotic lesion
produce an inflammatory cytokine interferon- (IFN ). IFN
acts on vascular smooth muscle cells to decrease the synthesis
of interstitial collagen (11, 12). IFN also inhibits smooth mus-
cle cell proliferation (13), helping reduction of collagen syn-
thesis in the atheromatous lesion. In addition, collagen break-
down by the proteolytic enzymes, such as metalloproteinas-
es (MMP) family, further weaken the fibrous cap (14, 15).
Since macrophages and smooth muscle cells are major cells
in atherosclerotic lesion, we are interested in the relation-
ship between the dietary intake of genistein and composi-
tion of macrophages and smooth muscle cells in the lesion.
In fact, lipid lowering reduces the number of macrophages
in experimental atherosclerosis and stabilizes the plaques by
reducing proteolytic activity (16, 17).
In this study, we investigated the effect of dietary genis-
tein on hypercholesterol diet-induced atherogenesis in rab-
bit aortas. We studied the effects of genistein supplementa-
tion on lesion progression, ratio of macrophages to smooth
muscle cells using immunohistochemistry. We also measured
matrix metalloproteinase-3 expression by western blotting
in the aortic wall.
MATERIALS AND METHODS
Animals and diets
Twenty eight young male New Zealand White rabbits
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Genistein Supplementation Inhibits Atherosclerosis with Stabilization
of the Lesions in Hypercholesterolemic Rabbits
The effect of genistein on aortic atherosclerosis was studied by immunohistochem-
istry with RAM-11 and HHF-35 antibodies and western blotting for matrix metallo-
proteinase-3 (MMP-3) in New Zealand White rabbits. After provocation of athero-
sclerosis with hyperlipidemic diet, the rabbits were divided as hyperlipidemic diet
group (HD), normal diet group (ND) and hyperlipidemic plus genistein diet group
(HD+genistein) for 4 and half months. The average cross sectional area of athero-
sclerotic lesion was 0.269 mm
2 after provocation. The lesion was progressed by
continuous hyperlipidemic diet (10.06 mm
2) but was increased mildly by genistein
(0.997 mm
2), and decreased by normal diet (0.228 mm
2). The ratio of macrophages
to smooth muscle cells in the lesion was not changed by genistein supplementa-
tion. The western blotting showed reduction of MMP-3 expression in HD+genistein
and ND groups than HD group. The inhibition of atherogenesis by genistein was
might be due to improve the endothelial dysfunction rather than direct action on
macrophages and/or smooth muscle cells in the lesion, since endothelial dysfunc-
tion by lipid peroxidation was the main atherogenic factor in the hypercholesterolemic
rabbits. The genistein supplementation also suggests that it helps the stabilization
of the atherosclerotic lesion by inhibition of MMP-3 expression.
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aged 5 weeks were obtained from Hanil Animal Laboratory
Co. (Wanju, Korea). Rabbits were individually housed in
metal cages in an air-conditioned room (22±1℃). Rabbits
were fed Purina
�rabbit diet (Agribrands Purina Korea, Korea)
for 2 weeks for adaptation. Rabbits had free access to tap
water. After two weeks, all rabbits were isolated and fed hyper-
cholesterol diet (HD: cholesterol 0.5% w/w; Sigma Chemi-
cal, St. Louis, MO, U.S.A.). The diet was prepared as pellet
and continued for 4 months for provoking atherosclerosis.
After provoking, 7 animals were euthanized for lesion eval-
uation and remaining 21 animals were randomly divided
into 3 groups: (1) 7 on ND, (2) 7 on HD, and (3) 7 on HD
plus Genistein diet (Genistein 1.65 mg/kg of rabbits; Onco-
gene, Fremont, CA, U.S.A.). Rabbits were fed the respec-
tive diets for another 4 and half months. At the end of 4 and
half months all animals were sacrificed for evaluation of the
aorta (Table 1).
Lesion observation 
The aortas were removed and both proximal and distal 1
cm of the aorta were freezed by liquid nitrogen and stored at
-80℃for molecular study. Others were fixed in 10% buffered
formalin solution. Two sections of 0.5 cm-length each from
the proximal, middle and distal portion (total 3 sections)
were embedded in paraffin (Paraplast, Oxford, St. Louis, MO,
U.S.A.) for light microscopy and immunohistochemistry.
Sections taken from each artery were stained with Verhoeff-
Van Gieson staining (18) and evaluated the development of
atherosclerotic lesion by image analyzer using Visus Image
Analysis System (Image and Microscopy Technology, Korea).
In short, we measured the round area consist of boundary line
along the intimal elastic lamina, and then we subtracted the
luminal area from each area. We considered it was a lesion
area. The lesion size was calculated from nine sections (three
sections from each block), and expressed as mean±SD.
Immunohistochemistry
Sections taken from each artery were evaluated for RAM 11
(DAKO Corporation, Carpinteria, CA, U.S.A.) and HHF-35
(DAKO) expression using an each monoclonal antibodies.
Simultaneous staining of slides from all groups has performed.
Four  m-thick paraffin sections from the arteries were incu-
bated with 3% hydrogen peroxide for five minutes, then with
0.5% casein-Tris buffer for thirty minutes for blocking non-
specific binding. The slides were incubated with anti-RAM
11 and HHF-35 for two hours. After incubation with species
appropriate biotinylated secondary antibodies (Vector Labo-
ratories, Vectorstain ABC kit; Vector Laboratories, Burlin-
game, CA, U.S.A.) for 30 min, washed and incubated with
streptavidin conjugated horseradish peroxidase (HRP) for 30
min. HRP visualization was carried out using 3,3′ -diamino-
benzidine tetrahydrochloride (ScyTek, Logan, Utah, U.S.A.)
as substrate. Sections were counterstained with Light Green
solution. Slides in which primary antibodies were omitted
served as negative controls for each antibody used in this study.
The brown-stained areas by anti-RAM 11 and anti-HHF-
35 antibodies were regarded as macrophages and smooth
muscle cell, respectively, and measured by the image ana-
lyzer.
Western blotting
Each tissue were homogenized in ice-cold buffer of 50 mM
Tris-HCl, pH 7.4/1 mM EDTA containing antipain (10  g/
mL), leupeptin (10  g/mL), and phenylmethylsulfonyl fluo-
ride (100  g/mL), and centrifuged at 4℃, 12,000 rpm for
30 min and supernatant collected. Protein content in each
sample was determined by a BioRad protein assay. Twenty  g
of protein in each were removed and mixed with 6×sodi-
um dodecyl sulfate (SDS) sample buffer (4×Tris-HCl/SDS
pH 6.8, glycerol (20%), SDS (1%), bromophenol blue (1.2%),
3 M Urea). The sample mixture was boiled at 100℃ for 5
min and loaded onto a 6% polyacrylamide mini-gel for SDS
polyacrylamide gel electrophoresis (SDS-PAGE). Proteins
separated on the minigel were transferred onto a nitrocellu-
lose membrane with a Bio-Rad transfer system at 80 V for
1 hr. The membrane was blocked with 5% nonfat dry milk
in PBS at room temperature for 1 hr and incubated at 4℃
overnight with mouse monoclonal antibody against rabbit
matrix metalloproteinase-3 (Oncogene, U.S.A.) diluted at
1:1,000 in blocking buffer. After washing with PBS contain-
ing 0.1% Tween-20, the membrane was incubated with a
horseradish peroxidase-conjugated anti-rabbit IgG secondary
antibody at room temperature for 1 hr. The membrane was
washed with PBS, developed by an enhanced chemilumines-
cence (Amersham Pharmacia Biotech, Buckinhamshire, U.K.)
western blot analysis system and exposed to Kodak XAR
radiography film.
Statistical analysis
Statistical analysis was performed using Students’ t-test
to evaluate difference between the sample of interest and its
respective control.







Control (7) HD None 
I: Hypercholesterol diet (HD) (7) HD HD
II: HD + Genistein (7) HD HD+Genistein
III: HD+ normocholesterol  HD ND 
diet (ND) (7)
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RESULTS
Lesion development 
The lesions were developed mildly during the provocation
period (average: 0.269 mm2), however, no aortas revealed any
gross or microscopic atherosclerotic lesion in the control group.
On light microscopic examination, the lesions consisted of
intimal hyperplastic lesion, which mainly composed of lipid-
laden macrophages (foam cell) and smooth muscle cells. There
were some variation of the lesions, but any fibrotic, calcific,
or thromobotic plaque lesion was not demonstrated. No mor-
phologic differences were demonstrated among experimen-
tal groups. All cholesterol-fed animals (ND, HD+G and
HD group) had a lesion on the aortic endothelium (Fig. 1).
The lesion is progressed by continuous hyperlipidemic diet
(average: 10.06 mm2), which is prevented partly by genistein
(average: 0.997 mm2). Normal diet decreased the lesion size
(average: 0.228 mm2).
The characteristic of atherosclerotic lesions
The immunohistochemistry for RAM-11 revealed diffuse
positive reaction in foamy cells and histiocytes in the lesion
(Fig. 2). The characteristic of the reaction was not different
among three experimental groups. The reactions with HHF-
35 antibody showed in the smooth muscle cells within the
lesion (Fig. 3). However, the staining intensities were slightly
weaker than RAM-11, although it revealed similar reaction
among the experimental groups. The average areas of positive
reaction to each antibody were measured by the image ana-
lyzer, and the ratio of RAM-11 to HHF-35 area was measured
(Fig. 4). There was no difference of statistical significance
between the experimental groups (p>0.05).
Western blotting for MMP-3
ND and HD+G groups show similar bands of intensity on
Western blotting with MMP-3. However, HD group revealed
stronger expression of MMP-3 (Fig. 5).
DISCUSSION
The genistein supplementation inhibits the atherogenesis
and decreases the MMP-3 expression in the aorta. However,
it has no or little effect on the ratio of macrophages/smooth
muscle cells in the aortic atherosclerotic lesions. 
Phytoestrogen has been known to have many anti-athero-
genic actions as described in the introduction, but there are
also some inconsistent reports on the action of phytoestrogen
on blood lipid concentration. Probably that is originated from
variable intestinal absorption in each experimental models
Fig. 2. Anti-RAM-11 immunohistochemical staining. There are strong staining of anti-RAM-11 in the superficial and deep areas of the athero-





























Control ND HD+GH D
Groups
Fig. 1. Aortic lesion development in rabbit aortas (Mean±SDs).
Genistein supplementation showed reduction of the lesion size.
ND, normal diet; HD, hypercholesterol diet; G, genistein; TA, tho-
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and/or different concentration of phytoestrogen in the diets
or materials. However, phytoestrogen or estrogen may have
bigger action in improving vascular functions than in just
reducing cholesterol (19-22), and this is independent of estro-
gen’s action on plasma lipids (20). Therefore, such action may
be a main mechanism in the decrease in ischemic heart dis-
ease in women treated with estrogen replacement (21).
Lipid peroxidation due to hyperlipidemic diet may be the
predominant factor of endothelial injury in this hypercholes-
terolemic model. Therefore, the inhibition of the atheroscle-
rotic lesion by genistein might be due to the improvement
of the endothelial dysfunction with decreasing oxidative mod-
ification of LDL cholesterol. Squadrito et al. (23) showed that
genistein supplementation improves endothelial dysfunction
in ovariectomized rats.
It is now widely accepted that atherosclerosis is a chronic
inflammatory process, and the lesion mainly consists of macro-
phages, lymphocytes, smooth muscle cells and extracellular
matrix containing lipid (24, 25). Since genistein has anti-
atherosclerotic action, it led us to hypothesize the genistein
also inhibits the inflammatory process in atherogenesis. We
have questioned whether genistein effects on the composi-
tion of histiocytes and/or smooth muscle cells in the lesion,
because these two cell types are main part in atherosclerosis.
But there was no difference between genistein addition and
no addition groups on the two cell types, at least in the com-
position. Several explanations would be possible for these
results. First, genistein has no direct effect on the macrophages-
smooth muscle cells in the inflammation. Second, the effects
of genistein on these two cells were similar. 
Fig. 3. Anti-HHF-35 immunohistochemical staining. Mild staining of anti-HHF-35 mainly in the deep areas of the atherosclerotic lesion.























Control ND HD+G HD
Groups
Fig. 4. The macrophage (M)/smooth muscle cell (SMC) ratio in the
atherosclerotic lesion in rabbit aortas. ND, normal diet; HD, hyper-
































Fig. 5. Inhibition of MMP-3 expression by Genstein (G) supple-
mentation in the thoracic aorta of hypercholesterolemic rabbits.
Relative optical density of MMP-3 was measured by densitome-
ter from Western blotting. ND, normal diet; HD, hypercholesterol
diet; G, genistein. *p<0.05.
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It has been suggested that one of the mechanisms by which
estrogen replacement therapy may reduce the cardiovascular
risk among postmenopausal women is the improving vascu-
lar reactivity (20-22). Since estrogen receptors are present in
the blood vessel wall (26), genistein is able to act as estrogen
agonist on the tissue (27). Some researches about phytoestro-
gen showed that it improved arterial stiffness (28) and poten-
tiated endothelium-dependent vasodilatation (7). Honore et
al. (29) reported that isoflavone enhances coronary vascular
reactivity in atherosclerotic female monkeys. 
Teede et al. (30) proposed that the reduction in arterial stiff-
ness by estrogen or phytoestrogen may be an important fac-
tor in the apparent reduction in cardiovascular risk as demon-
strated in epidemiological studies. A significant number of
acute thrombotic occlusion that develops between angiograms
occur in arterial segments that were angiographically normal
or mildly irregular in the first angiogram (31). Practically,
the acute, often unheralded, onset of symptoms in acute myo-
cardial infarction suggests that pre-existing coronary stenoses
susceptible to acute thrombotic occlusion in the infarct-relat-
ed artery may not necessarily have been severe (32). In addi-
tion, the vulnerable plaques occur across the full spectrum of
severity of stenosis, and disruption of a plaque causing min-
imal stenosis is more likely to invoke an acute ischemic episode
because of the lack of prior collateral development (33). Rioufol
et al. (34) suggested that the acute coronary syndrome is more
connected with overall coronary instability rather than one
single lesion when observed by their intravascuar ultrasound
study. Therefore, the character of the atherosclerotic lesions
may be more important than the size itself.
Aikawa et al. (35) demonstrated that lipid lowering by
dietary manipulation significantly reduces proteolytic activ-
ity and increases collagen content of estabilished atheroma
in rabbits, when MMP-1 activity was measured. Bocan et al.
(36) showed that MMP expression was reduced by cholesterol
esterification enzyme inhibitor. Their results suggested that
lipid lowering may stabilize vulnerable plaques by reduced
activity of the enzymes that degrade the arterial extracellular
matrix, and render atheroma less susceptible to disruption
and thrombosis by favoring collagen accumulation in the
fibrous cap. In fact, with atherosclerotic lesion development,
the expression of matrix metalloproteinase-1, -3, -7, and 9
increase (37, 38).
In this experiment, we could see decreased MMP-3 expres-
sion in the aorta in genistein supplementation and lipid lower-
ing rabbits. The decreased expression of the enzyme may con-
tribute to stabilization of the lesion, since the enzyme involved
in plaque rupture in the advanced lesion. 
We conclude that genistein, a type of phytoestrogen, inhibits
aortic atherosclerosis initiated by hyperlipidemic diet in rab-
bits. The mechanism for this lesion inhibition might be due
to decrease endothelial dysfunction by inhibiting oxidative
modification of LDL cholesterol, rather than direct action
on macrophage or smooth muscle cells in the atherosclerotic
lesion. 
The results also suggest that genistein may represent a good
candidate to substitute estrogens in the prevention of athero-
sclerosis for stabilization of the atherosclerotic lesion. We
think further studies are needed for understanding of mech-
anism of anti-atherogenic action of phytoestrogen.
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